Vertex Pharmaceuticals Incorporated
521.12USD
-7.7800 (-1.47%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 8.9B | 9.9B | 11.0B | 12.0B | 13.3B | 14.5B |
| Q1 | 2.1B | 2.4B | 2.7B | 2.8B | 3.0B | — |
| Q2 | 2.2B | 2.5B | 2.6B | 3.0B | 3.3B | — |
| Q3 | 2.3B | 2.5B | 2.8B | 3.1B | 3.4B | — |
| Q4 | 2.3B* | 2.5B* | 2.9B* | 3.2B* | 3.5B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 12.82 | 13.89 | -2.08 | 15.32 | 15.90 | 20.23 |
| Q1 | 2.96 | 2.69 | 4.21 | 2.49 | 4.02 | — |
| Q2 | 3.13 | 3.52 | -13.92 | 3.99 | 4.31 | — |
| Q3 | 3.59 | 3.97 | 4.01 | 4.20 | -2.35 | — |
| Q4 | 3.16* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 3.72* |
| 3.54* |
| 4.62* |
| 4.61 |
| — |